Technical Analysis for SNCA - Seneca Biopharma, Inc.

Grade Last Price % Change Price Change
D 1.56 -0.64% -0.01
SNCA closed up 6.08 percent on Wednesday, April 21, 2021, on 14 percent of normal volume.
Earnings due: Apr 23
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical SNCA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.64%
Wide Bands Range Expansion -0.64%
Wide Bands Range Expansion 5.41%
Oversold Stochastic Weakness 5.41%
Bullish Engulfing Bullish 0.65%
Stochastic Buy Signal Bullish 0.65%
Wide Bands Range Expansion 0.65%
Oversold Stochastic Weakness 0.65%
Narrow Range Bar Range Contraction 12.23%
NR7 Range Contraction 12.23%
Older End-of-Day Signals for SNCA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 3 hours ago
50 DMA Resistance about 3 hours ago
60 Minute Opening Range Breakout about 5 hours ago
Up 1% about 5 hours ago
Down 3% about 7 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Seneca Biopharma, Inc. Description

Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been completed Phase II clinical trials for the treatment of major depressive disorder; and NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as in Phase II clinical trial for the treatment of chronic ischemic stroke and in Phase I clinical trial for the treatment of chronic spinal cord injury. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cells Injury Stroke Major Depressive Disorder Depressive Disorder Amyotrophic Lateral Sclerosis Spinal Cord Neuron Treatment Of Major Depressive Disorder Spinal Cord Injury Stem Cell Therapy Ischemic Stroke Antisense Therapy Chemical Entity

Is SNCA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.67
52 Week Low 0.5001
Average Volume 3,650,530
200-Day Moving Average 1.00
50-Day Moving Average 1.59
20-Day Moving Average 1.62
10-Day Moving Average 1.53
Average True Range 0.19
ADX 21.16
+DI 26.56
-DI 18.57
Chandelier Exit (Long, 3 ATRs ) 2.11
Chandelier Exit (Short, 3 ATRs ) 1.90
Upper Bollinger Band 1.91
Lower Bollinger Band 1.33
Percent B (%b) 0.41
BandWidth 36.17
MACD Line -0.03
MACD Signal Line 0.00
MACD Histogram -0.0233
Fundamentals Value
Market Cap 27.15 Million
Num Shares 17.3 Million
EPS -5.88
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 508.63
Price-to-Book 0.78
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.78
Resistance 3 (R3) 1.76 1.68 1.74
Resistance 2 (R2) 1.68 1.62 1.68 1.73
Resistance 1 (R1) 1.62 1.59 1.65 1.64 1.72
Pivot Point 1.54 1.54 1.55 1.55 1.54
Support 1 (S1) 1.48 1.48 1.51 1.50 1.42
Support 2 (S2) 1.40 1.45 1.41 1.41
Support 3 (S3) 1.34 1.40 1.40
Support 4 (S4) 1.36